View More View Less
  • 1 Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szeged, Semmelweis u. 1., 6725
  • | 2 Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szeged
Restricted access

Absztrakt:

A világ egyes részein a népesség nagyarányú növekedése komoly gazdasági és népegészségügyi kihívást jelent, míg más országokban a hatékony fogamzásgátlási igényt személyes motivációk határozzák meg. A jelenleg széles körben hozzáférhető fogamzásgátlási módszerek java része a nők feladata, míg igen korlátozott azoknak a módszereknek a száma, amelyekért a férfi a felelős. Korábbi tanulmányok alapján ismert, hogy a terhességek jelentős hányada nem kívánt terhesség, illetve, hogy lehetőség esetén a férfiak a fogamzásgátlásban nagyobb szerepet vállalnának. Többek között emiatt indultak el az elmúlt évtizedekben olyan vizsgálatok, amelyek egy megfelelő férfi hormonális fogamzásgátlási módszer kifejlesztését tűzték ki célul. A módszer alapja a külsőleg bevitt hatóanyaggal az agyalapi mirigy folliculusstimuláló és luteinizáló hormon elválasztásának gátlása, amely következményesen gátolja a here tesztoszteron- és spermiumtermelését is. A témában megjelent tanulmányok először tesztoszteronszármazékot, majd annak elégtelensége miatt tesztoszteron-gesztagén kombinációt alkalmaztak, később megjelentek a szintetikus androgén vegyületek is. Az elért eredmények egyelőre nem teszik lehetővé az ilyen jellegű fogamzásgátló módszerek biztonságos, széles körű alkalmazását, de a jövőben elképzelhető, hogy az akadályok leküzdését követően, a fogamzásgátlás területén a férfiak is több lehetőséget kapnak. Orv Hetil. 2017; 158(46): 1819–1830.

  • 1

    Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plann. 2014; 45: 301–314.

  • 2

    Tsui AO, McDonald-Mosley R, Burke AE. Family planning and the burden of unintended pregnancies. Epidemiol Rev. 2010; 32: 152–174.

  • 3

    Johnson S, Pion C, Jennings V. Current methods and attitudes of women towards contraception in Europe and America. Reprod Health 2013; 10: 7.

  • 4

    Kozinszky Z, Bártfai G. Contraceptive behaviour of teenagers requesting abortion. Eur J Obstet Gynecol Reprod Biol. 2004; 112: 80–83.

  • 5

    Ross J, Hardee K. Use of male methods of contraception worldwide. J Biosoc Sci. 2017; 49: 648–663.

  • 6

    Kopa Zs. Male contraception. In: Papp Z. (ed.) Handbook of gynecology. [A férfi fogamzásgátlás. In: Papp Z. (szerk.) A nőgyógyászat kézikönyve.] Medicina Könyvkiadó, Budapest, 2017; pp. 271–276. [Hungarian]

  • 7

    Dohle GR, Diemer T, Kopa Z, et al. European Association of Urology guidelines on vasectomy. Eur Urol. 2012; 61: 159–163.

  • 8

    Elek C, Dudás I, Czeizel E. Surgical sterilization and health practices in birth control policy. [A művi meddővététel és az egészségkultúra a születéskorlátozásban.] Orv Hetil. 1990; 131: 887. [Hungarian]

  • 9

    Herrel LA, Goodman M, Goldstein M, et al. Outcomes of microsurgical vasovasostomy for vasectomy reversal: a meta-analysis and systematic review. Urology 2015; 85: 819–825.

  • 10

    Martin CW, Anderson RA, Cheng L, et al. Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod. 2000; 15: 637–645.

  • 11

    Chao JH, Page ST. The current state of male hormonal contraception. Pharmacol Ther. 2016; 163: 109–117.

  • 12

    World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990; 336: 955–959.

  • 13

    World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996; 65: 821–829.

  • 14

    McLachlan RI, McDonald J, Rushford D. Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception. Contraception 2000; 62: 73–78.

  • 15

    Wang C, Wang XH, Nelson AL, et al. Levonorgestrel implants enhanced the suppression of spermatogenesis by testosterone implants: comparison between Chinese and non-Chinese men. J Clin Endocrinol Metab. 2006; 91: 460–470.

  • 16

    Glasier A. Acceptability of contraception for men: a review. Contraception 2010; 82: 453–456.

  • 17

    Yin AY, Htun M, Swerdloff RS, et al. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation. J Androl. 2012; 33: 190–201.

  • 18

    Gonzalo IT, Swerdloff RS, Nelson AL, et al. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002; 87: 3562–3572.

  • 19

    Zhang GY, Gu YQ, Wang XH, et al. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl. 1998; 19: 761–768.

  • 20

    Gu YQ, Wang XH, Xu D, et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab. 2003; 88: 562–568.

  • 21

    Gu Y, Liang X, Wu W, et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab. 2009; 94: 1910–1915.

  • 22

    Handelsman DJ, Mackey MA, Howe C. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol (Oxf). 1997; 47: 311–316.

  • 23

    Attardi BJ, Koduri S, Hild SA. Relative progestational and androgenic activity of four progestins used for male hormonal contraception assessed in vitro in relation to their ability to suppress LH secretion in the castrate male rat. Mol Cell Endocrinol. 2010; 328: 16–21.

  • 24

    Zitzmann M, Rohayem J, Raidt J, et al. Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial. Andrology 2017; 5: 516–526.

  • 25

    Bebb RA, Anawalt BD, Christensen RB, et al. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab. 1996; 81: 757–762.

  • 26

    Anawalt BD, Amory JK, Herbst KL, et al. Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. J Androl. 2005; 26: 405–413.

  • 27

    Hay CJ, Brady BM, Zitzmann M, et al. A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. J Clin Endocrinol Metab. 2005; 90: 2042–2049.

  • 28

    Anawalt BD, Herbst KL, Matsumoto AM, et al. Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Fertil Steril. 2000; 74: 707–714.

  • 29

    Brady BM, Amory JK, Perheentupa A, et al. A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Hum Reprod. 2006; 21: 285–294.

  • 30

    Mommers E, Kersemaekers WM, Elliesen J, et al. Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2008; 93: 2572–2580.

  • 31

    Ilani N, Roth MY, Amory JK, et al. A new combination of testosterone and nestorone transdermal gels for male hormonal contraception. J Clin Endocrinol Metab. 2012; 97: 3476–3486.

  • 32

    Roth MY, Shih G, Ilani N, et al. Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception 2014; 90: 407–412.

  • 33

    Roth MY, Ilani N, Wang C, et al. Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone® gels. Andrology 2013; 1: 899–905.

  • 34

    Behre HM, Zitzmann M, Anderson RA, et al. Efficacy and safety of an injectable combination hormonal contraceptive for men. J Clin Endocrinol Metab. 2016; 101: 4779–4788.

  • 35

    Qoubaitary A, Meriggiola C, Ng CM, et al. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. J Androl. 2006; 27: 853–867.

  • 36

    Page ST, Amory JK, Anawalt BD, et al. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab. 2006; 91: 4374–4380.

  • 37

    Turner L, Conway AJ, Jimenez M, et al. Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab. 2003; 88: 4659–4667.

  • 38

    Roth MY, Nya-Ngatchou JJ, Lin K, et al. Androgen synthesis in the gonadotropin-suppressed human testes can be markedly suppressed by ketoconazole. J Clin Endocrinol Metab. 2013; 98: 1198–1206.

  • 39

    Surampudi P, Page ST, Swerdloff RS, et al. Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive. Andrology 2014; 2: 579–587.

  • 40

    Von Eckardstein S, Noe G, Brache V, et al. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab. 2003; 88: 5232–5239.

  • 41

    Walton MJ, Kumar N, Baird DT, et al. 7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. J Androl. 2007; 28: 679–688.

  • 42

    McLachlan RI, Robertson DM, Pruysers E, et al. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab. 2004; 89: 142–149.

  • 43

    Page ST, Kalhorn TF, Bremner WJ, et al. Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. J Androl. 2007; 28: 734–741.

  • 44

    Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010; 95: 2560–2575.

  • 45

    Liu PY, Swerdloff RS, Christenson PD, et al. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 2006; 367: 1412–1420.

  • 46

    Krisfalusi M, Miki K, Magyar PL. Multiple glycolytic enzymes are tightly bound to the fibrous sheath of mouse spermatozoa. Biol Reprod. 2006; 75: 270–278.

  • 47

    Zdrojewicz Z, Konieczny R, Papier P, et al. Brdt bromodomains inhibitors and other modern means of male contraception. Adv Clin Exp Med. 2015; 24: 705–714.

  • 48

    O’Rand MG, Silva EJ, Hamil KG. Non-hormonal male contraception: A review and development of an Eppin based contraceptive. Pharmacol Ther. 2016; 157: 105–111.

  • 49

    Barda S, Paz G, Yogev L. Expression of BET genes in testis of men with different spermatogenic impairments. Fertil Steril. 2012; 97: 46–52.e5.

  • 50

    Bianchi E, Doe B, Goulding D, et al. Juno is the egg Izumo receptor and is essential for mammalian fertilization. Nature 2014; 508: 483–487.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 23 0 1
Feb 2021 33 3 5
Mar 2021 37 2 3
Apr 2021 30 2 3
May 2021 31 1 2
Jun 2021 17 0 0
Jul 2021 0 0 0